bjgabrielsen

ExoDx Urine Prostate Test to Evaluate Risk of Aggressive Prostate Cancer Prior to First Biopsy.

The ExoDx Prostate Test is a non-invasive, non-digital rectal exam, urine test used as a risk assessment tool to provide risk probabilities for aggressive prostate cancer. The technology relies on cancer-specific genomic biomarkers found in the urine. The test analyzes three cancer-specific biomarkers found in the urine associated with aggressive prostate cancer: ERG, PCA and more »

New Guidelines for Care of Advanced Prostate Cancer

The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have released new guidelines for the diagnosis and treatment of advanced prostate cancer, developed by a panel of experts. In addition to their own expertise and experience, panel members assessed data from 264 prostate cancer studies in developing more »

Active Surveillance Video

Dr. Mark Scholz, Executive Director of the Prostate Cancer Research Institute (PCRI), has produced three very informative short videos dealing with topics such as 1) active surveillance (AS) for men recently diagnosed with prostate cancer, 2) bone metastasis and, 3) diet and cancer. This first 7 minute AS video defines the terms “watchful waiting” as more »

A Large, Free, Virtual Prostate Cancer Conference Available Sept. 11-13, 2020.

The annual Prostate Cancer Research Institute (PCRI) Conference is a comprehensive educational experience for prostate cancer patients and caregivers. The conference moderated by Mark Moyad, MD, consists of keynote presentations from leading doctors followed by live question – and – answer sessions. Keynote topics include all treatments, newly-diagnosed, diet and exercise, sexual dysfunction, active surveillance, more »

Lessons From a Live Oak Tree.

This morning I experienced a brief but annoying episode of a recurrent medical issue and potentially a new one. My initial reaction was tension mixed with a little “worry” and “what if”. I have been down that same road before. Almost immediately, God’s Word from James 1:6-7 came to me. “For the one who doubts more »

Adding Provenge to Xtandi or Zytiga Reduces Risk of Death by 45% in Metastatic Hormone Resistant Prostate Cancer

Data from more than 6,000 Medicare patients showed that adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extended the lives of men with metastatic hormone-resistant prostate cancer (mCRPC). The findings were presented in a poster at the recent American Society of Clinical Oncology (ASCO) more »

Put Your Hope in God

Several years ago, I experienced an annoying side effect which had arisen related to earlier prostate cancer therapy. The side effect had been “cured” by a specific series of treatments but now it had reared its troublesome head again. One recent Sunday, it was especially troublesome. There are potential treatments for this condition but my more »

A Life of Peace

This website usually focuses exclusively on prostate cancer but this particular post could apply to the current worldwide coronavirus pandemic as well. Right now we as a nation and many of us as individuals may have a potential medical problem that has our stomach in knots with persistent worry. For most of us, it is more »

Molecular Imaging PSMA PET/CT Could Transform Management of People with Aggressive Cancer

Upon recent discussions with my urologist and oncologist, they both informed me that the following is a highly significant development in imaging of prostate cancer. A medical imaging technique, known as PSMA PET/CT, that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for more »

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer in Men with BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration (hormone)-resistant prostate cancer (mCRPC) and BRCA mutations. Clovis submitted its application to the FDA in November, 2019. The priority review status will shorten Rubraca’s regulatory review for this more »

A Clinical Trial for Men With Low – Intermediate Risk Prostate Cancer Considering Radiation Therapy.

The National Cancer Institute (NCI) is sponsoring a clinical trial at many locations comparing two types of radiation therapy, stereotactic body radiation therapy (SBRT) with intensity-modulated radiation therapy (IMRT). The former is administered in less than two weeks while the latter is given in five weeks. The aim of the trial is to compare cure more »

Prostate Cancer Foundation (PCF) 2019 Guide

Every year, the PCF publishes an electronic guide providing information on all aspects of prostate cancer. The chapters covered are as follows. General information including diagnosis, symptoms, risk factors, and medical basics. Information for the newly diagnosed, including detection, diagnosis and treatment selection. Treatment options for localized or locally advanced prostate cancer. These include active more »